All News

Article

Canada's 2025 Top 10 Funded Rheumatology Projects

Arthritis Society Feb 02, 2026

Arthritis Society Canada (ASC) is Canada’s largest charitable funder of cutting-edge arthritis research, investing more than $240 million in research projects since its founding, and over $7 million invested in 2024-2025. Below are the investigators and projects that were funded in 2025.

Article

Methotrexate intolerance in rheumatoid arthritis

Jack Cush, MD Feb 02, 2026

A current large rheumatoid arthritis (RA) cohort study from Cairo assessed methotrexate (MTX) use and found over half were MTX intolerant and a third of patients were noncompliant with MTX.

Article

RheumNow Live Preview (1.30.2026)

Jack Cush, MD Jan 30, 2026

Dr. Jack Cush reviews the news and journal reports from RheumNow.com - and the top 5 reasons to attend RheumNow Live 2026, which is one week away.

Article

Notch and TGFβ Signaling in Refractory Rheumatoid Arthritis

EurekAlert! Jan 29, 2026

Spatial transcriptomic profiling of rheumatoid arthritis (RA) synovial biopsies (pre- and post-treatment) has revealed new insights into the pathobiology or treatment resistent RA.

Article

Difficult to Treat Rheumatoid Arthritis

Jack Cush, MD Jan 29, 2026

Dr. Cush addresses the management of difficult-to-treat rheumatoid arthritis (D2TRA).

2016 ARTIC trial tested T2T w/ MTX & "bridging" tapered Prednisolone (15 mg --> 0mg over 7wks) in 237 new DMARD naive RA pts. PRED discontinuation successful in 84% @7wks, 89% @3mos, 95% @ 24 mos. Only 5% require Pred @ every visit for 2 yrs. You can D/C pred! https://t.co/O23PHq81YP

Notch and TGFβ Signaling in Refractory Rheumatoid Arthritis Spatial transcriptomic profiling of rheumatoid arthritis (RA) synovial biopsies (pre- and post-treatment) has revealed new insights into the pathobiology or treatment resistent RA. https://t.co/vCvFpnIOvS https://t.co/EV6OihT0br

Notch and TGFβ Signaling in Refractory Rheumatoid Arthritis | RheumNow

Full read review of the Mechanistic Effects of Methotrexate in the Treatment of Rheumatoid Arthritis. https://t.co/PrMyZ7q3wX download here: https://t.co/aRnmRm770Z https://t.co/5B0mBjzOXQ

Clinical contributors to pathogenesis and treatment outcomes for rheumatoid arthritis. Full read review of pathogenesis and unmet needs in #RA https://t.co/IEC0tsp1Rk https://t.co/jIsqhy9rQh

https://buff.ly/Qoe08T0

Testing for RF, CCP, ESR and CRP Check out the accompanying Advanced Practice Rheum: Rheumatoid and Inflammation Testing video. https://t.co/4hkDO1M2UD https://t.co/APRKYLAS3k

Testing for RF, CCP, ESR and CRP | RheumNow

APPIPRA Study - Benefits of Early Treatment Treating people who are at high risk of rheumatoid arthritis (RA) can delay the onset of the disease for several years, with benefits also continuing well after treatment has stopped. https://t.co/GYguq7VlqT https://t.co/5Z0BXIm3cM

APPIPRA Study - Benefits of Early Treatment | RheumNow

Remission? Single center study of 100 RA, 100 SLE pts assessed by SLEDAI-2K, SDAI, VAS. Remission/LDA found in 88% of 392 SLE visits & 91% of 389 RA visits(p=NS). Remission was more common in SLE vs RA (79% vs 69%; p= 0.0018). https://t.co/ZPRrYQMsCT

Treating-to-target: remission and low disease activity in systemic lupus erythe…

Physical activity (PA) is assoc w/ reduced all-cause mortality in RA pts. Study of 1493 NHANES & 1724 UK Biobank RA cohorts showing robust inverse association between PA and all-cause mortality (HR: active = 0.48, highly active = 0.61) https://t.co/K6ALzqP3QQ https://t.co/2XJ0zD7FA3

Association between physical activity and all-cause mortality in rheumatoid art…

Full read review of the Mechanistic Effects of Methotrexate in the Treatment of Rheumatoid Arthritis. https://t.co/PrMyZ7q3wX download here: https://t.co/fvEocwsXIv https://t.co/ZWVctochHV

Minnesota Mayo clinic retrospective, population study of RF & CCP in 1373 incident RA pts. At Dx, 37% dual seropositive, 13% +CCP only, 12% +RF only, & 38% seronegative. zDual seropositives had more erosions (31%) & flares (69% vs 51%). But +RF only highest mortality (adj 2.18) https://t.co/hPQewVgPoq

Clinical contributors to pathogenesis and treatment outcomes for rheumatoid arthritis. Full read review of pathogenesis and unmet needs in #RA https://t.co/OZxOuXdnIq https://t.co/LuYoLVfb7N

https://buff.ly/YhNBKDB

Rheum Poll> Which is the most difficult to treat RA (D2TRA) patient (despite aggressive Rx)?

Testing for RF, CCP, ESR and CRP Check out the accompanying Advanced Practice Rheum: Rheumatoid and Inflammation Testing video. https://t.co/o1sle6CKg5 https://t.co/roYXcbPdBh

https://buff.ly/IwISMRq

Rheum Poll> Which is the most difficult to treat RA (D2TRA) patient (despite aggressive Rx)?

BIOBADASER III Registry shows No Cancer Risk with b/tsDMARDs A large, real-world cohort study of rheumatoid arthritis (RA) finds patients treated with biologic and targeted synthetic DMARDs (b/tsDMARDs) do not have an increased risk of cancer. https://t.co/0oawv88Anq https://t.co/nrsok06gKV

https://buff.ly/Se5J5Un

Topics

All News

Canada's 2025 Top 10 Funded Rheumatology Projects

Methotrexate intolerance in rheumatoid arthritis

RheumNow Live Preview (1.30.2026)

Notch and TGFβ Signaling in Refractory Rheumatoid Arthritis

Difficult to Treat Rheumatoid Arthritis

Do you get our email newsletter?